Literature DB >> 1727646

ZK98299--a new antiprogesterone: biochemical characterization of steroid binding parameters in the calf uterine cytosol.

R Nath1, A Bhakta, V K Moudgil.   

Abstract

We have examined steroid binding characteristics of a newly synthesized antisteroid, ZK98299 [onapristone, 11 beta-(4-dimethylaminophenyl)-17 alpha-hydroxy-17 beta-(3-hydroxypropyl)- 13 alpha-methyl-4,9-gonadien-3-one], in the calf uterus cytosol and compared the nature of this interaction with the binding of progesterone receptor (PR) agonist R5020 [promegestone, 17,21-dimethylpregna-4,9-diene-3,20-dione]. In the freshly prepared cytosol, [3H]ZK98299 interacted specifically with a macromolecule: the binding was abolished in the presence of excess progestins (R5020 and progesterone) and the antiprogesterone ZK98299. The high affinity (Kd = 2.5 nM) interaction between [3H]ZK98299 and PR was temperature- and time-dependent, reaching an optimum by 2-3 h at 0 degrees C, and was facilitated by 20 mM Na2MoO4. Under nontransforming conditions, [3H]ZK98299-receptor complexes sedimented as 8 S species in 8-30% linear glycerol gradients. Upon salt or thermal transformation, there was a loss of the 8 S form, with only a small fraction of total complexes (5-7%) binding to DNA-cellulose. In contrast, transformed [3H]R5020-receptor complexes exhibited a greater extent of binding (25-55%) to DNA-cellulose. [3H]ZK98299-receptor complexes could be resolved into two ionic species over DEAE-Sephacel following incubation of the complexes at 0 or 23 degrees C. [3H]ZK98299 binding was sensitive to sulfhydryl group modification as beta-mercaptoethanol increased the extent of steroid binding. Although treatment with iodoacetamide (IA) abolished [3H]R5020 binding, there was a significant (nearly twofold) increase in the [3H]ZK98299 binding. The results of this study point to similarities and differences between the steroid binding properties of the uterine PR occupied by R5020 and ZK98299: both steroids appear to bind the same 8 S receptor but exhibit differential DNA binding and sensitivity to IA. The reported antagonist properties of ZK98299 may, therefore, be explained on the basis of a distinct receptor conformation induced by the antisteroid.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727646     DOI: 10.1016/0003-9861(92)90083-9

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

1.  In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA.

Authors:  K Delabre; A Guiochon-Mantel; E Milgrom
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

2.  Effects of antiprogestins on the rate of proliferation of breast cancer cells.

Authors:  K Iwasaki; B Underwood; M Herman; S Dinda; S Kodali; H J Kloosterboer; C Hurd; V K Moudgil
Journal:  Mol Cell Biochem       Date:  1999-08       Impact factor: 3.396

3.  Interaction of newly synthesized antiprogesterone ZK98299 with progesterone receptor from human myometrium.

Authors:  A D'souza; I N Hinduja; S Kodali; V K Moudgil; C P Puri
Journal:  Mol Cell Biochem       Date:  1994-10-12       Impact factor: 3.396

4.  Interaction of cycloalkanoprogesterones with mammalian progesterone receptor: binding of pregna-D'-pentaranes in the calf uterine cytosol.

Authors:  A Bhakta; M Herman; I S Levina; V K Moudgil
Journal:  Mol Cell Biochem       Date:  1993-08-25       Impact factor: 3.396

5.  Onapristone Extended Release: Safety Evaluation from Phase I-II Studies with an Emphasis on Hepatotoxicity.

Authors:  James H Lewis; Paul H Cottu; Martin Lehr; Evan Dick; Todd Shearer; William Rencher; Alice S Bexon; Mario Campone; Andrea Varga; Antoine Italiano
Journal:  Drug Saf       Date:  2020-10       Impact factor: 5.606

Review 6.  Hypothalamic Astrocyte Development and Physiology for Neuroprogesterone Induction of the Luteinizing Hormone Surge.

Authors:  Kevin Sinchak; Margaret A Mohr; Paul E Micevych
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-26       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.